Protein modification by ubiquitination has emerged as a critical regulatory event in virtually all aspects of cell biology. Ubiquitination is a reversible process, and ubiquitin moieties can be removed from polypeptides by deubiquitinating enzymes (DUBs). TGF-? is a cytokine with a key role in tissue homeostasis and cancer. In advanced tumours TGF-? switches from a tumour suppressor role to one as an oncogenic factor by inducing pro-invasive and pro-metastatic responses. We have recently identified a number of DUBs, which are overexpressed in glioblastoma, breast and ovarian cancers that act as potent activators of TGF-? pathway. Dr Eichhorn is interested in studying the regulation of these DUBs on the TGF-? pathway and their role in cancer progression.